XERIS BIOPHARMA HOLDINGS, INC. Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount of $98.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationOtherReconcilingItems · last filed 2026-03-02
- XERIS BIOPHARMA HOLDINGS, INC. effective income tax rate reconciliation, other reconciling items, amount for fiscal 2025 was $98.00K, a 90.43% decline from fiscal 2024.
- XERIS BIOPHARMA HOLDINGS, INC. effective income tax rate reconciliation, other reconciling items, amount for fiscal 2024 was $1.02M, a 146.75% increase from fiscal 2023.
- XERIS BIOPHARMA HOLDINGS, INC. effective income tax rate reconciliation, other reconciling items, amount for fiscal 2023 was $415.00K, a 74.79% decline from fiscal 2022.
- XERIS BIOPHARMA HOLDINGS, INC. effective income tax rate reconciliation, other reconciling items, amount for fiscal 2022 was $1.65M, a 429.26% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount 12 month | Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $98.00K 10-K · filed 2026-03-02 | |
| 2024-12-31 | $1.02M 10-K · filed 2026-03-02 | |
| 2023-12-31 | $415.00K 10-K · filed 2026-03-02 | $131.00K 10-K · filed 2024-03-06 |
| 2022-12-31 | $1.65M 10-K · filed 2025-03-06 | $506.00K 10-K · filed 2023-03-08 |
| 2021-12-31 | $311.00K 10-K · filed 2024-03-06 | |
| 2020-12-31 | -$141.00K 10-K · filed 2022-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |